login
login

Europe Daily Bulletin No. 8129

16 January 2002
Contents Publication in full By article 38 / 41
ECONOMIC INTERPENETRATION / (eu) pharmaceuticals

Franco-German group AVENTIS has decided to outsource some of its clinical research activities in Germany through a joint venture with the British risk capital firm 3I. No financial details have been given - the deal covers an AVENTIS PHARMA laboratory in Frankfurt. The holding company for the lab is called COVIDENCE - some 40% of it is held by AVENTIS, 30% by 3I and 30% by staff and managers.

Contents

A LOOK BEHIND THE NEWS
THE DAY IN POLITICS
GENERAL NEWS
ECONOMIC INTERPENETRATION